v3.26.1
Segment Reporting - Summary of Operating Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting            
External R&D expense $ 58,234   $ 62,401   $ 110,048 $ 111,079
Equity-based compensation expense         37,907 37,846
Depreciation and amortization expense         632 810
Loss on disposal of property and equipment         3 0
Other non-operating expense/(income), net (570)   (127)   (1,360) (171)
Net loss 109,896 $ 105,510 110,031 $ 74,723 215,406 184,754
Operating segment            
Segment Reporting            
Employee related expense [1] 37,445   32,484   74,971 55,422
External expense - G&A 16,597   14,952   32,729 23,895
Other segment items [2] 6,573   6,273   13,082 11,531
Equity-based compensation expense 19,662   24,433   37,907 37,846
Depreciation and amortization expense 297   417   632 810
Loss on disposal of property and equipment         3  
Other non-operating expense/(income), net 995   (2,078)   4,489 (4,445)
Net loss 109,896   110,031   $ 215,406 184,754
Description-Other segment related expense         Consists of other segment expenses related to supplies, corporate and facilities expenses.  
Operating segment | Apitegromab            
Segment Reporting            
External R&D expense 22,948   27,956   $ 43,209 47,257
Operating segment | SRK-181            
Segment Reporting            
External R&D expense 9   792   45 1,902
Operating segment | SRK-439            
Segment Reporting            
External R&D expense 3,760   2,575   5,519 6,854
Operating segment | Early research and other            
Segment Reporting            
External R&D expense $ 1,610   $ 2,227   $ 2,820 $ 3,682
[1] Excludes equity-based compensation expense.
[2] Consists of other segment expenses related to supplies, corporate and facilities expenses.